drugset
drugset / Trial / NCT00097760

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00097760 ↗

Phase 2 Completed 110 enrolled Biogen Elan Pharmaceuticals · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).

Timeline

Start
2003-06
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject natalizumab Monoclonal antibody 300 mg Intravenous
Background Glatiramer Acetate Small molecule 20 mg Subcutaneous

Indications

relapsing-remitting multiple sclerosis